ATMP Sweden’s Post

View organization page for ATMP Sweden, graphic

6,361 followers

Welcome Elicera Therapeutics AB to ATMP Sweden membership! A stellar example of the spin out of Swedish innovation 😍 If you missed our article on how their i-TANK technology tricks the immune system into thinking the tumour is a bacterial infection.....you can read up here https://lnkd.in/gM7KeW9X. ABOUT Elicera Therapeutics AB is a cell and gene therapy company in the clinical phase developing the next generation iTANK-enabled CAR T-cell therapies and oncolytic viruses. The company has two ongoing Phase I/II clinical studies: The CARMA-study (CAR T-cell therapy for treatment of B-cell lymphoma) and the AdVince-study (oncolytic virus (OV) for the treatment of neuroendocrine tumours. In addition Elicera is developing two candidates in the preclinical phase: ELC-401 (CAR T-cell therapy for treatment of glioblastoma) and ELC-201 (OV for treatment of solid tumours). The proprietary iTANK-platform aims to meet two of the biggest challenges of CAR T-cell therapies for the treatment of solid tumours: a very heterogenous ett mycket heterogent target antigen expression and a hostile tumour microenvironment. iTANK has been demonstrated to enhance the function of CAR T-cells by activating a parallel immune defense against the tumour via CD8+ killer T-cells. This strategy is expected to have broad application to induce attack on the majority of tumour targets on cancer cells. The iTANK-platform can be universally adapted to other CAR T-cell therapies.

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics